Hemodynamic Therapeutics

Hemodynamic Therapeutics is a clinical-stage biotechnology company dedicated to the development of transformative therapies for patients with advanced liver disease and its complications. The company's primary focus is on portal hypertension, a critical driver of morbidity and mortality in cirrhosis. Its lead candidate, HT-001, is a highly selective vasopressin V1a receptor agonist engineered to provide potent vasoconstriction in the splanchnic circulation while minimizing the off-target effects on V1b and V2 receptors seen with non-selective agents. Based in Edinburgh, the company leverages deep expertise in hepatology and cardiovascular pharmacology to address significant unmet needs in hepatorenal syndrome and other liver-related vascular disorders.